A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients With Locally Advanced or Metastatic Cancers
Ontology highlight
ABSTRACT: Gene sets enriched in tumor tissue in response to dosing with ivuxolimab from eight paired biopsies of patients dosed with ≥ 1.5 mg/kg indicated that gene sets associated with immune activation and inflammation were among those most enriched (higher positive normalized enrichment score [NES]) with the lowest adjusted P values.
ORGANISM(S): Homo sapiens
PROVIDER: GSE184752 | GEO | 2021/11/10
REPOSITORIES: GEO
ACCESS DATA